Taiwan FDA registration 6142d2b631b676d3d2e5e4262e8230df
Primmos CLC385 variant hemoglobin test group
TW: 普林莫斯CLC385變異血色素試驗組
Taiwan·Risk Class 2·Trinity Biotech (Primus Corporation dba Trinity Biotech)·Registered Feb 10, 2006 – Feb 10, 2021CancelledRegistration details
- Analysis ID
- 6142d2b631b676d3d2e5e4262e8230df
- Customs Code
- DHA00601598101
Company information
- Manufacturer Country
- United States
- Authorized Representative
- PROGRESSIVE GROUP INC.
Product details
- Intended Use
- High-pressure liquid chromatography is used for in vitro diagnosis of whole blood or diluted specimens to quantify the variant hemoglobin of normal people or patients.
- Product Type (Level 1)
- B Hematology, pathology, and genetics
- Product Type (Level 2)
- B.7415 Abnormal hemoglobin analysis
- Import Information
- import
Dates and status
- Registration Date
- Feb 10, 2006
- Expiry Date
- Feb 10, 2021
- Cancellation Date
- Sep 19, 2023
Cancellation information
- Status
- Logged out
- Reason
- 自行鍵入
About this record
Access comprehensive regulatory information for Primmos CLC385 variant hemoglobin test group in Taiwan's medical device market through Pure Global AI's free database. This Risk Class 2 medical device is registered under number 6142d2b631b676d3d2e5e4262e8230df and manufactured by Trinity Biotech (Primus Corporation dba Trinity Biotech). The authorized representative in Taiwan is PROGRESSIVE GROUP INC..
This page provides complete technical specifications, regulatory compliance details. Pure Global AI offers free access to 89,000+ Taiwan medical device registrations, helping global MedTech companies navigate Taiwan FDA regulations, identify competitors, and discover partnership opportunities efficiently.
Free DatabasePowered by Pure Global AI89,000+ Devices